An essential part of regaining your health, staying healthy and getting ready for stem cell therapy is chelation! To understand why this is true a little background is needed:
There are two general types of poisons that affect our bodies – heavy metals and chemicals. Heavy metals include lead, mercury, cadmium, etc. which react with oxygen, glucose, etc. to produce free radicals which damage tissues where the metals are embedded in the body.
Metals such as copper, zinc, iron, etc. are usually a part of the structures of proteins in living organisms. If these metals are released into tissues, they react with oxygen and form free radicals. Heavy metals such as lead and mercury sabotage the body’s free radical mop up system which basically keeps them from forming molecules with unpaired electrons. These free radical electrons then can react with other molecules and form a chain reaction of destruction. The result is that your tissue “spoils” or becomes “rancid”. These “rancid” membranes are a major part of aging and disease. One of the biggest challenges in reversing aging and chronic disease processes is to actually reverse this “rancidity” of diseased tissues. Chelation removes the basic cause behind the formation of “rancid” membranes by removing the free metals that bring about the formation of “rancid” oxidized cell membranes.
EDTA chelation is endorsed for the treatment of atherosclerotic vascular disease by the American College for Advancement in Medicine (ACAM), comprising of 750 licensed physicians. Its proponents claim that EDTA consistently improves blood flow and relieves symptoms associated with atherosclerosis in over 80% of the patients treated. In early studies, it was observed that patients being treated for acute lead intoxication with EDTA and who had cardiovascular disease showed improved stress tolerance and less chest pain with physical exertion. In 1956 Norman Clarke published an article in the American Journal of Medical Science on the successful treatment of patients with severe angina pectoris through the use of EDTA.
In 1988, Drs. Olszewer and Carter reported on the treatment of 2870 patients with EDTA chelation therapy. Over 93% of the patients who suffered from narrowed coronary arteries showed good to excellent improvement. 97% of those with narrowed leg arteries showed improvement and 60% of patients with narrowed brain arteries showed increased circulation from EDTA chelation.
More than one million patients have received over twenty million infusions to-date. No significant adverse effects have been reported when the ACAM protocol has been followed. Early reports of renal injury and more recent adverse effects resulted from excessive doses being given (greater than 50 mg/Kg/day), from infusions that were too fast (less than three hours), and from failing to replace calcium, magnesium and other nutrients that are recommended in the ACAM protocol.
The benefits of EDTA chelation are proposed to include:
In summary, arteries become hardened and non-elastic as atherosclerosis develops. EDTA chelation therapy “softens” these hardened arteries by reducing the collagen and elastin cross linkages by removing the metals that are generating the cross-linking free radicals.
Chelation is gaining acceptance in conventional medicine as an adjunct treatment for Alzheimer’s Disease. By removing unbound iron, copper, aluminum, zinc, etc. in the brain, which generate free radicals and contribute to the development of collagen and elastin cross linking by free radicals (as advanced glycation end products), chelation assists in blocking the factors that contribute to diabetes, atherosclerosis, neurodegenerative diseases including Alzheimer’s, and aging.
In addition the NIH conducted a multicenter medical trial with EDTA chelation for atherosclerosis. Previous studies were flawed in that the ACAM protocol was not followed. There is also the need for the drip to be sufficiently slow and for the patient’s blood to be checked through the week to insure that essential minerals are maintained within the normal range.
When this study was completed, the results were summarized as follows:
“A $30 million National Institutes of Health-funded trial to assess the safety and efficacy of EDTA chelation therapy in 1708 post-myocardial infarction (MI) patients was completed in 2014. The trial demonstrated a significant (P=0.035) 18% reduction in a combined primary endpoint of death, MI, stroke, coronary revascularization or hospitalization of angina. In diabetic patients the benefit was more impressive, with a 41% relative reduction in risk (P=0.0002) and a 43% reduction in total mortality (P=0.011). Safety data were also favorable. A reduction of oxidative stress by chelation of toxic metals has been proposed as a possible mechanism of action.”